VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 10, 2007) - Tekmira Pharmaceuticals Corporation (“Tekmira”) (TSX: TKM) reported today that its partner Hana Biosciences, Inc. (NASDAQ: HNAB) presented Marqibo® (vincristine sulfate injection, OPTISOME™) clinical and non-clinical data at the 49th Annual Meeting of the American Society of Hematology (ASH) on December 8, 2007. The ASH meeting is being held December 8-11, 2007 in Atlanta, Georgia.
